{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:07:07Z","timestamp":1790698027000,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T00:00:00Z","timestamp":1493856000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s00259-017-3699-z","type":"journal-article","created":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T02:38:27Z","timestamp":1493865507000},"page":"1455-1462","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Comparison of PSMA-HBED and PSMA-I&amp;T as diagnostic agents in prostate carcinoma"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0991-7539","authenticated-orcid":false,"given":"Michael","family":"McCarthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Langton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,4]]},"reference":[{"issue":"11","key":"3699_CR1","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S","volume":"82","author":"DG Bostwick","year":"1998","unstructured":"Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82(11):2256\u201361.","journal-title":"Cancer"},{"issue":"1","key":"3699_CR2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/1078-1439(95)00002-Y","volume":"1","author":"GL Wright Jr","year":"1995","unstructured":"Wright Jr GL, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol. 1995;1(1):18\u201328.","journal-title":"Urol Oncol"},{"issue":"17","key":"3699_CR3","first-page":"6357","volume":"9","author":"JS Ross","year":"2003","unstructured":"Ross JS, Sheehan CE, Fisher HA, Kaufman Jr RP, Kaur P, Gray K, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003;9(17):6357\u201362.","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research."},{"issue":"2","key":"3699_CR4","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0090-4295(96)00184-7","volume":"48","author":"GL Wright Jr","year":"1996","unstructured":"Wright Jr GL, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48(2):326\u201334.","journal-title":"Urology"},{"issue":"1","key":"3699_CR5","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clinical cancer research : an official journal of the American Association for Cancer Research. 1997;3(1):81\u20135.","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"issue":"5","key":"3699_CR6","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.humpath.2006.11.012","volume":"38","author":"S Perner","year":"2007","unstructured":"Perner S, Hofer MD, Kim R, Shah RB, Li H, Moller P, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007;38(5):696\u2013701.","journal-title":"Hum Pathol"},{"issue":"2","key":"3699_CR7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","volume":"42","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET\/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(2):197\u2013209.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"3699_CR8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","volume":"41","author":"A Afshar-Oromieh","year":"2014","unstructured":"Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11\u201320.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"3699_CR9","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","volume":"70","author":"M Perera","year":"2016","unstructured":"Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70(6):926\u201337.","journal-title":"Eur Urol"},{"issue":"supplement 2","key":"3699_CR10","first-page":"61","volume":"57","author":"M Eiber","year":"2016","unstructured":"Eiber M, Heck M, Tauber R, Rauscher I, D\u2019Alessandria C, Maurer T, et al. Systemic radioligand therapy with 177Lu-PSMA I&T in patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57(supplement 2):61.","journal-title":"J Nucl Med"},{"issue":"supplement 1","key":"3699_CR11","first-page":"1083","volume":"55","author":"M Weineisen","year":"2014","unstructured":"Weineisen M, Schottelius M, Simecek J, Eiber M, Schwaiger M, Wester H. Development and first in human evaluation of PSMA I&T - a ligand for diagnostic imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2014;55(supplement 1):1083.","journal-title":"J Nucl Med"},{"issue":"11","key":"3699_CR12","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2967\/jnumed.115.161299","volume":"56","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The Theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET\/CT: Biodistribution in humans, radiation Dosimetry, and first evaluation of tumor lesions. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2015;56(11):1697\u2013705.","journal-title":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine."},{"issue":"6","key":"3699_CR13","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2967\/jnumed.114.147413","volume":"56","author":"M Benesova","year":"2015","unstructured":"Benesova M, Schafer M, Bauder-Wust U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and Endoradiotherapy of prostate cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2015;56(6):914\u201320.","journal-title":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine."},{"issue":"5","key":"3699_CR14","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1021\/acs.jmedchem.5b01210","volume":"59","author":"M Benesova","year":"2016","unstructured":"Benesova M, Bauder-Wust U, Schafer M, Klika KD, Mier W, Haberkorn U, et al. Linker modification strategies to control the prostate-specific membrane antigen (PSMA)-targeting and pharmacokinetic properties of DOTA-conjugated PSMA inhibitors. J Med Chem. 2016;59(5):1761\u201375.","journal-title":"J Med Chem"},{"issue":"5","key":"3699_CR15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1053\/j.semnuclmed.2016.04.004","volume":"46","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Afshar-Oromieh A, Kopka K, Haberkorn U, Giesel FL. Current status of prostate-specific membrane antigen targeting in nuclear medicine: clinical translation of Chelator containing prostate-specific membrane antigen ligands into diagnostics and therapy for prostate cancer. Semin Nucl Med. 2016;46(5):405\u201318.","journal-title":"Semin Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-017-3699-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-017-3699-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-017-3699-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T05:39:46Z","timestamp":1499751586000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-017-3699-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,4]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["3699"],"URL":"https:\/\/doi.org\/10.1007\/s00259-017-3699-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,4]]}}}